Health · 11 views
STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
Source STAT AI Summary Updated May 30, 2026
Health 
Story intelligence Beta
Freshness Stale Updated May 30, 2026
Confidence Limited Single-outlet story
Coverage Single outlet
Views 11 Community interest
Read time 1 min ~16 words
AI Summary
CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
Read full article on StatnewsAI summaries can be wrong sometimes—always verify important details using the source article.
SUPPORT HAPPENINGNOW · Independent AI News Intelligence
Enjoyed this article? Consider supporting HappeningNow to help keep independent AI-powered news analysis moving forward. Your contribution helps cover infrastructure, AI summaries, and continued platform development.
Support HappeningNowMore from Health
Continue reading recent Health coverage